Clinical trial
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the…
NCT00045786 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00045786 |
|---|---|
| Title | Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes |
| Official title | A Multi-center, An Open Label, Dose-Escalation Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment for Myelodysplastic Syndromes |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | CC-1088 |
| Enrollment | 18 |
| Start date | Oct 1, 2001 |
| Primary completion | Dec 1, 2001 |
| Completion | Nov 1, 2003 |
| First posted | Sep 11, 2002 |
| Last update posted | Apr 25, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: